$9.85
-0.64-6.1%
Ult. Agg.: Nov 17, 12:36 PM

The average analyst price target for Generate Biomedicines is $26.40, 168.0% above the current price. Of 6 analysts, 6 rate it Buy. Targets range from $22 to $30. The latest change came on Aug 28, 2026, when HC Wainwright & Co. raised its price target on Generate Biomedicines from $25 to $30 and kept a Buy rating.
Price Target Range — 4 Quarters
Analyst Consensus — 6 Analysts
Rating Trend — Last 9 Months